Ovid Therapeutics Inc.
OVID
$1.56
-$0.01-0.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 945.89% | 1,070.95% | 15.61% | 44.39% | 113.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 945.89% | 1,070.95% | 15.61% | 44.39% | 113.30% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 945.89% | 1,070.95% | 15.61% | 44.39% | 113.30% |
| SG&A Expenses | -9.42% | -17.85% | -3.52% | -3.48% | -9.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.17% | -27.75% | -3.05% | 9.96% | 28.19% |
| Operating Income | 39.29% | 37.14% | 3.20% | -9.72% | -27.72% |
| Income Before Tax | -11.78% | -28.34% | 50.72% | 49.50% | 33.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.78% | -28.34% | 50.72% | 49.50% | 33.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.78% | -28.34% | 50.72% | 49.50% | 33.02% |
| EBIT | 39.29% | 37.14% | 3.20% | -9.72% | -27.72% |
| EBITDA | 39.38% | 37.46% | 3.33% | -9.74% | -28.08% |
| EPS Basic | -11.75% | -28.50% | 51.07% | 49.42% | 34.81% |
| Normalized Basic EPS | -1.27% | -14.87% | 48.35% | 38.62% | 22.43% |
| EPS Diluted | -11.12% | -27.41% | 51.39% | 49.78% | 34.63% |
| Normalized Diluted EPS | -1.21% | -14.80% | 48.30% | 38.57% | 22.38% |
| Average Basic Shares Outstanding | 0.35% | 0.42% | 0.49% | 0.46% | 0.42% |
| Average Diluted Shares Outstanding | 0.25% | 0.32% | 0.59% | 0.56% | 0.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |